Abstract
Summary
Acromegaly is a rare endocrine disorder characterized by excessive production of growth hormone, which may lead to abnormal growth of the bones and soft tissues, including the face, hands, and feet. The management of acromegaly includes both medical and surgical options.
The global market for Management of Acromegaly was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of %during the forecast period 2024-2030.
North American market for Management of Acromegaly was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Management of Acromegaly was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Management of Acromegaly was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Management of Acromegaly include Pfizer Inc., Chiasma Inc, Novartis AG, Ipsen Biopharmaceuticals Inc, Wockhardt Ltd., Troikaa Pharmaceuticals Limited, VHB Life Sciences Limited, GlaxoSmithKline plc, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
The Management of Acromegaly market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Management of Acromegaly.
Market Segmentation
By Company
Pfizer Inc.
Chiasma Inc
Novartis AG
Ipsen Biopharmaceuticals Inc
Wockhardt Ltd.
Troikaa Pharmaceuticals Limited
VHB Life Sciences Limited
GlaxoSmithKline plc
Segment by Type
Ectopic Acromegaly
Pseudo Acromegaly
Segment by Application
Surgery
Drug Therapy
Radiation Therapy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Management of Acromegaly company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Management of Acromegaly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Management of Acromegaly in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Management of Acromegaly was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of %during the forecast period 2024-2030.
North American market for Management of Acromegaly was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Management of Acromegaly was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Management of Acromegaly was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Management of Acromegaly include Pfizer Inc., Chiasma Inc, Novartis AG, Ipsen Biopharmaceuticals Inc, Wockhardt Ltd., Troikaa Pharmaceuticals Limited, VHB Life Sciences Limited, GlaxoSmithKline plc, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
The Management of Acromegaly market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Management of Acromegaly.
Market Segmentation
By Company
Pfizer Inc.
Chiasma Inc
Novartis AG
Ipsen Biopharmaceuticals Inc
Wockhardt Ltd.
Troikaa Pharmaceuticals Limited
VHB Life Sciences Limited
GlaxoSmithKline plc
Segment by Type
Ectopic Acromegaly
Pseudo Acromegaly
Segment by Application
Surgery
Drug Therapy
Radiation Therapy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Management of Acromegaly company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Management of Acromegaly in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Management of Acromegaly in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Management of Acromegaly Product Introduction
1.2 Global Management of Acromegaly Market Size Forecast (2019-2030)
1.3 Management of Acromegaly Market Trends & Drivers
1.3.1 Management of Acromegaly Industry Trends
1.3.2 Management of Acromegaly Market Drivers & Opportunity
1.3.3 Management of Acromegaly Market Challenges
1.3.4 Management of Acromegaly Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Management of Acromegaly Players Revenue Ranking (2023)
2.2 Global Management of Acromegaly Revenue by Company (2019-2024)
2.3 Key Companies Management of Acromegaly Manufacturing Base Distribution and Headquarters
2.4 Key Companies Management of Acromegaly Product Offered
2.5 Key Companies Time to Begin Mass Production of Management of Acromegaly
2.6 Management of Acromegaly Market Competitive Analysis
2.6.1 Management of Acromegaly Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Management of Acromegaly Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Management of Acromegaly as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Ectopic Acromegaly
3.1.2 Pseudo Acromegaly
3.2 Global Management of Acromegaly Sales Value by Type
3.2.1 Global Management of Acromegaly Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Management of Acromegaly Sales Value, by Type (2019-2030)
3.2.3 Global Management of Acromegaly Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Surgery
4.1.2 Drug Therapy
4.1.3 Radiation Therapy
4.2 Global Management of Acromegaly Sales Value by Application
4.2.1 Global Management of Acromegaly Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Management of Acromegaly Sales Value, by Application (2019-2030)
4.2.3 Global Management of Acromegaly Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Management of Acromegaly Sales Value by Region
5.1.1 Global Management of Acromegaly Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Management of Acromegaly Sales Value by Region (2019-2024)
5.1.3 Global Management of Acromegaly Sales Value by Region (2025-2030)
5.1.4 Global Management of Acromegaly Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Management of Acromegaly Sales Value, 2019-2030
5.2.2 North America Management of Acromegaly Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Management of Acromegaly Sales Value, 2019-2030
5.3.2 Europe Management of Acromegaly Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Management of Acromegaly Sales Value, 2019-2030
5.4.2 Asia Pacific Management of Acromegaly Sales Value by Region (%), 2023 VS 2030
5.5 South America
5.5.1 South America Management of Acromegaly Sales Value, 2019-2030
5.5.2 South America Management of Acromegaly Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Management of Acromegaly Sales Value, 2019-2030
5.6.2 Middle East & Africa Management of Acromegaly Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Management of Acromegaly Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Management of Acromegaly Sales Value, 2019-2030
6.3 United States
6.3.1 United States Management of Acromegaly Sales Value, 2019-2030
6.3.2 United States Management of Acromegaly Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Management of Acromegaly Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Management of Acromegaly Sales Value, 2019-2030
6.4.2 Europe Management of Acromegaly Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Management of Acromegaly Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Management of Acromegaly Sales Value, 2019-2030
6.5.2 China Management of Acromegaly Sales Value by Type (%), 2023 VS 2030
6.5.3 China Management of Acromegaly Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Management of Acromegaly Sales Value, 2019-2030
6.6.2 Japan Management of Acromegaly Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Management of Acromegaly Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Management of Acromegaly Sales Value, 2019-2030
6.7.2 South Korea Management of Acromegaly Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Management of Acromegaly Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Management of Acromegaly Sales Value, 2019-2030
6.8.2 Southeast Asia Management of Acromegaly Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Management of Acromegaly Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Management of Acromegaly Sales Value, 2019-2030
6.9.2 India Management of Acromegaly Sales Value by Type (%), 2023 VS 2030
6.9.3 India Management of Acromegaly Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Profile
7.1.2 Pfizer Inc. Main Business
7.1.3 Pfizer Inc. Management of Acromegaly Products, Services and Solutions
7.1.4 Pfizer Inc. Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Inc. Recent Developments
7.2 Chiasma Inc
7.2.1 Chiasma Inc Profile
7.2.2 Chiasma Inc Main Business
7.2.3 Chiasma Inc Management of Acromegaly Products, Services and Solutions
7.2.4 Chiasma Inc Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.2.5 Chiasma Inc Recent Developments
7.3 Novartis AG
7.3.1 Novartis AG Profile
7.3.2 Novartis AG Main Business
7.3.3 Novartis AG Management of Acromegaly Products, Services and Solutions
7.3.4 Novartis AG Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.3.5 Novartis AG Recent Developments
7.4 Ipsen Biopharmaceuticals Inc
7.4.1 Ipsen Biopharmaceuticals Inc Profile
7.4.2 Ipsen Biopharmaceuticals Inc Main Business
7.4.3 Ipsen Biopharmaceuticals Inc Management of Acromegaly Products, Services and Solutions
7.4.4 Ipsen Biopharmaceuticals Inc Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.4.5 Ipsen Biopharmaceuticals Inc Recent Developments
7.5 Wockhardt Ltd.
7.5.1 Wockhardt Ltd. Profile
7.5.2 Wockhardt Ltd. Main Business
7.5.3 Wockhardt Ltd. Management of Acromegaly Products, Services and Solutions
7.5.4 Wockhardt Ltd. Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.5.5 Wockhardt Ltd. Recent Developments
7.6 Troikaa Pharmaceuticals Limited
7.6.1 Troikaa Pharmaceuticals Limited Profile
7.6.2 Troikaa Pharmaceuticals Limited Main Business
7.6.3 Troikaa Pharmaceuticals Limited Management of Acromegaly Products, Services and Solutions
7.6.4 Troikaa Pharmaceuticals Limited Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.6.5 Troikaa Pharmaceuticals Limited Recent Developments
7.7 VHB Life Sciences Limited
7.7.1 VHB Life Sciences Limited Profile
7.7.2 VHB Life Sciences Limited Main Business
7.7.3 VHB Life Sciences Limited Management of Acromegaly Products, Services and Solutions
7.7.4 VHB Life Sciences Limited Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.7.5 VHB Life Sciences Limited Recent Developments
7.8 GlaxoSmithKline plc
7.8.1 GlaxoSmithKline plc Profile
7.8.2 GlaxoSmithKline plc Main Business
7.8.3 GlaxoSmithKline plc Management of Acromegaly Products, Services and Solutions
7.8.4 GlaxoSmithKline plc Management of Acromegaly Revenue (US$ Million) & (2019-2024)
7.8.5 GlaxoSmithKline plc Recent Developments
8 Industry Chain Analysis
8.1 Management of Acromegaly Industrial Chain
8.2 Management of Acromegaly Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Management of Acromegaly Sales Model
8.5.2 Sales Channel
8.5.3 Management of Acromegaly Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer